JP5943441B2 - エネルギーによる神経調節 - Google Patents
エネルギーによる神経調節 Download PDFInfo
- Publication number
- JP5943441B2 JP5943441B2 JP2015082029A JP2015082029A JP5943441B2 JP 5943441 B2 JP5943441 B2 JP 5943441B2 JP 2015082029 A JP2015082029 A JP 2015082029A JP 2015082029 A JP2015082029 A JP 2015082029A JP 5943441 B2 JP5943441 B2 JP 5943441B2
- Authority
- JP
- Japan
- Prior art keywords
- energy
- ultrasound
- nerve
- renal
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000005036 nerve Anatomy 0.000 title claims description 347
- 230000033228 biological regulation Effects 0.000 title description 3
- 238000002604 ultrasonography Methods 0.000 claims description 301
- 210000004204 blood vessel Anatomy 0.000 claims description 163
- 238000003384 imaging method Methods 0.000 claims description 133
- 238000000034 method Methods 0.000 claims description 123
- 238000002679 ablation Methods 0.000 claims description 61
- 238000012360 testing method Methods 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 12
- 230000036961 partial effect Effects 0.000 claims description 11
- 238000001931 thermography Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000012014 optical coherence tomography Methods 0.000 claims description 6
- 238000012879 PET imaging Methods 0.000 claims description 5
- 238000003331 infrared imaging Methods 0.000 claims description 5
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 4
- 210000002254 renal artery Anatomy 0.000 description 168
- 238000011282 treatment Methods 0.000 description 158
- 210000003734 kidney Anatomy 0.000 description 143
- 210000001367 artery Anatomy 0.000 description 94
- 238000002595 magnetic resonance imaging Methods 0.000 description 91
- 230000001225 therapeutic effect Effects 0.000 description 91
- 210000001519 tissue Anatomy 0.000 description 78
- 230000002889 sympathetic effect Effects 0.000 description 77
- 210000003491 skin Anatomy 0.000 description 57
- 210000000709 aorta Anatomy 0.000 description 36
- 238000004088 simulation Methods 0.000 description 34
- 230000003902 lesion Effects 0.000 description 32
- 210000003403 autonomic nervous system Anatomy 0.000 description 30
- 238000002591 computed tomography Methods 0.000 description 30
- 210000002796 renal vein Anatomy 0.000 description 30
- 210000003484 anatomy Anatomy 0.000 description 29
- 238000010438 heat treatment Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 27
- 238000013459 approach Methods 0.000 description 26
- 230000036772 blood pressure Effects 0.000 description 26
- 230000006378 damage Effects 0.000 description 26
- 230000006870 function Effects 0.000 description 25
- 230000033001 locomotion Effects 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 210000001508 eye Anatomy 0.000 description 23
- 210000003101 oviduct Anatomy 0.000 description 23
- 210000000614 rib Anatomy 0.000 description 23
- 230000008685 targeting Effects 0.000 description 23
- 230000017531 blood circulation Effects 0.000 description 22
- 238000004422 calculation algorithm Methods 0.000 description 22
- 206010020772 Hypertension Diseases 0.000 description 21
- 229940079593 drug Drugs 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 210000000988 bone and bone Anatomy 0.000 description 19
- 239000003504 photosensitizing agent Substances 0.000 description 18
- 210000003462 vein Anatomy 0.000 description 18
- 206010002329 Aneurysm Diseases 0.000 description 17
- 238000013461 design Methods 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 16
- 210000000331 sympathetic ganglia Anatomy 0.000 description 16
- 210000000467 autonomic pathway Anatomy 0.000 description 15
- 239000000835 fiber Substances 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 210000004126 nerve fiber Anatomy 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 238000002059 diagnostic imaging Methods 0.000 description 13
- 210000002216 heart Anatomy 0.000 description 13
- 230000005865 ionizing radiation Effects 0.000 description 13
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 12
- 108091008698 baroreceptors Proteins 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 229960002748 norepinephrine Drugs 0.000 description 12
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 12
- 210000001774 pressoreceptor Anatomy 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000005855 radiation Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 210000004100 adrenal gland Anatomy 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000008035 nerve activity Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000012285 ultrasound imaging Methods 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000000944 nerve tissue Anatomy 0.000 description 8
- 210000000578 peripheral nerve Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000001235 sensitizing effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000005166 vasculature Anatomy 0.000 description 8
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000001326 carotid sinus Anatomy 0.000 description 7
- 238000002091 elastography Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- -1 veldine Chemical compound 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229960002749 aminolevulinic acid Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical group [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 6
- 229960004657 indocyanine green Drugs 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 210000001032 spinal nerve Anatomy 0.000 description 6
- 239000004575 stone Substances 0.000 description 6
- 210000002820 sympathetic nervous system Anatomy 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000002517 zygapophyseal joint Anatomy 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 208000002667 Subdural Hematoma Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000009529 body temperature measurement Methods 0.000 description 5
- 210000003451 celiac plexus Anatomy 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 4
- 208000000913 Kidney Calculi Diseases 0.000 description 4
- 206010029148 Nephrolithiasis Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000001011 carotid body Anatomy 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000002638 denervation Effects 0.000 description 4
- 210000000609 ganglia Anatomy 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 210000000273 spinal nerve root Anatomy 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 238000003325 tomography Methods 0.000 description 4
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010015769 Extradural haematoma Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010057469 Vascular stenosis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009910 autonomic response Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000001363 mesenteric artery superior Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 3
- 230000007383 nerve stimulation Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 230000033458 reproduction Effects 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- GEDVVYWLPUPJJZ-UHFFFAOYSA-N (7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride Chemical compound [Cl-].N1=C2C=CC(=[N+](C)C)C=C2SC2=C1C=C(C)C(N)=C2 GEDVVYWLPUPJJZ-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000034827 Neointima Diseases 0.000 description 2
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 2
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000012152 algorithmic method Methods 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000008321 arterial blood flow Effects 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000000746 body region Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 108091008690 chemoreceptors Proteins 0.000 description 2
- IZMHKHHRLNWLMK-UHFFFAOYSA-M chloridoaluminium Chemical compound Cl[Al] IZMHKHHRLNWLMK-UHFFFAOYSA-M 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 229960003569 hematoporphyrin Drugs 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229940109328 photofrin Drugs 0.000 description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 2
- 210000002979 radial nerve Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000574 retroperitoneal space Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000004861 thermometry Methods 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical compound C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- PGIGZWJIJSINOD-UHFFFAOYSA-N 12h-benzo[a]phenothiazine Chemical compound C1=CC=CC2=C3NC4=CC=CC=C4SC3=CC=C21 PGIGZWJIJSINOD-UHFFFAOYSA-N 0.000 description 1
- LEQCIMQTUCPCFD-UHFFFAOYSA-N 1lambda3-chlora-2-azacyclohexa-1,3,5-triene Chemical compound C1=CN=[Cl]C=C1 LEQCIMQTUCPCFD-UHFFFAOYSA-N 0.000 description 1
- KXSFECAJUBPPFE-UHFFFAOYSA-N 2,2':5',2''-terthiophene Chemical compound C1=CSC(C=2SC(=CC=2)C=2SC=CC=2)=C1 KXSFECAJUBPPFE-UHFFFAOYSA-N 0.000 description 1
- RHBJMYOTXIENOZ-UHFFFAOYSA-N 2-[10,15,20-tris(2-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol Chemical compound Oc1ccccc1-c1c2ccc(n2)c(-c2ccccc2O)c2ccc([nH]2)c(-c2ccccc2O)c2ccc(n2)c(-c2ccccc2O)c2ccc1[nH]2 RHBJMYOTXIENOZ-UHFFFAOYSA-N 0.000 description 1
- FNPOHMCPKIQLBU-UHFFFAOYSA-J 3-[20-(carboxylatomethyl)-18-(dioxidomethylidene)-8-ethenyl-13-ethyl-3,7,12,17-tetramethyl-2,3-dihydroporphyrin-23-id-2-yl]propanoate;hydron;tin(4+) Chemical compound [H+].[Sn+4].C1=C([N-]2)C(CC)=C(C)C2=CC(C(=C2C)C=C)=NC2=CC(C(C2CCC([O-])=O)C)=NC2=C(CC([O-])=O)C2=NC1=C(C)C2=C([O-])[O-] FNPOHMCPKIQLBU-UHFFFAOYSA-J 0.000 description 1
- BTQAFTBKHVLPEV-UHFFFAOYSA-N 3h-naphtho[2,3-e]indazole Chemical compound C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- WCSNGEFLXVCIHA-UHFFFAOYSA-N C(#N)C(=C(C#N)C#N)C#N.C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C3=C(C(N1)=C2)C=CC=C3 Chemical group C(#N)C(=C(C#N)C#N)C#N.C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C3=C(C(N1)=C2)C=CC=C3 WCSNGEFLXVCIHA-UHFFFAOYSA-N 0.000 description 1
- CYPINGSGZRKLPH-UHFFFAOYSA-N C(CC)(=O)NC1=C(C=CC=C1)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2 Chemical compound C(CC)(=O)NC1=C(C=CC=C1)C1=C2NC(=C1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2 CYPINGSGZRKLPH-UHFFFAOYSA-N 0.000 description 1
- JUDGRMABQJKRPW-XIADSQHASA-N CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C Chemical class CCC1=C(/C=C2\N=C(/C(\CC3=O)=C(/[C@@H](CCC(O)=O)[C@@H]4C)\N/C\4=C\C(C(C)=C4C=C)=N/C\4=C4)C3=C\2C)NC/4=C1C JUDGRMABQJKRPW-XIADSQHASA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000542420 Sphyrna tudes Species 0.000 description 1
- 208000031809 Subdural Acute Hematoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- QGKVXWDADKTZHW-UHFFFAOYSA-N azaporphyrin Chemical compound C1=C(N=2)C=CC=2C=C(N=2)C=CC=2C=C(N2)C=CC2=CC2=CNC1=N2 QGKVXWDADKTZHW-UHFFFAOYSA-N 0.000 description 1
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- DGAZLNHJYDOWLG-QWRGUYRKSA-N cercosporin Chemical compound C[C@H](O)CC1=C(OC)C(=O)C2=C(O)C=C3OCOC4=CC(O)=C5C6=C4C3=C2C1=C6C(C[C@H](C)O)=C(OC)C5=O DGAZLNHJYDOWLG-QWRGUYRKSA-N 0.000 description 1
- JWFLIMIGORGZMQ-UHFFFAOYSA-N cercosporin Natural products COC1=C(CC(C)O)c2c3c(CC(C)O)c(OC)c(O)c4C(=O)C=C5OCOc6cc(O)c(C1=O)c2c6c5c34 JWFLIMIGORGZMQ-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003099 femoral nerve Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- VANSZAOQCMTTPB-SETSBSEESA-N hypocrellin Chemical compound C1[C@@](C)(O)[C@@H](C(C)=O)C2=C(OC)C(O)=C3C(=O)C=C(OC)C4=C3C2=C2C3=C4C(OC)=CC(=O)C3=C(O)C(OC)=C21 VANSZAOQCMTTPB-SETSBSEESA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MXLWQNCWIIZUQT-UHFFFAOYSA-N isocercosporin Natural products O=C1C=C2OCOC3=CC(=O)C4=C5C3=C2C2=C1C(O)=C(OC)C(CC(C)O)=C2C5=C(CC(C)O)C(OC)=C4O MXLWQNCWIIZUQT-UHFFFAOYSA-N 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 108091008704 mechanoreceptors Proteins 0.000 description 1
- 210000001617 median nerve Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical class [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 210000004249 mesenteric artery inferior Anatomy 0.000 description 1
- 210000001758 mesenteric vein Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical class [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 238000002355 open surgical procedure Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008663 renal system process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- BQJKVFXDDMQLBE-UHFFFAOYSA-N shiraiachrome A Natural products COC1=C2C3=C(OC)C=C(O)C4=C3C3=C5C(CC(C)(O)C(C(C)=O)C3=C(OC)C4=O)=C(OC)C(=O)C(C(O)=C1)=C25 BQJKVFXDDMQLBE-UHFFFAOYSA-N 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- YNHJECZULSZAQK-UHFFFAOYSA-N tetraphenylporphyrin Chemical class C1=CC(C(=C2C=CC(N2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3N2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 YNHJECZULSZAQK-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000000658 ulnar nerve Anatomy 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/320068—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4035—Evaluating the autonomic nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4041—Evaluating nerves condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4041—Evaluating nerves condition
- A61B5/4047—Evaluating nerves condition afferent nerves, i.e. nerves that relay impulses to the central nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4887—Locating particular structures in or on the body
- A61B5/489—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4887—Locating particular structures in or on the body
- A61B5/4893—Nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/032—Transmission computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/506—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of nerves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/06—Measuring blood flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/320068—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic
- A61B2017/320069—Surgical cutting instruments using mechanical vibrations, e.g. ultrasonic for ablating tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00404—Blood vessels other than those in or around the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00434—Neural system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00505—Urinary tract
- A61B2018/00511—Kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/374—NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/376—Surgical systems with images on a monitor during operation using X-rays, e.g. fluoroscopy
- A61B2090/3762—Surgical systems with images on a monitor during operation using X-rays, e.g. fluoroscopy using computed tomography systems [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/378—Surgical systems with images on a monitor during operation using ultrasound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/022—Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthalmodynamometers
- A61B5/0225—Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthalmodynamometers the pressure being controlled by electric signals, e.g. derived from Korotkoff sounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
- A61B5/4041—Evaluating nerves condition
- A61B5/4052—Evaluating nerves condition efferent nerves, i.e. nerves that relay impulses from the central nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
- A61B5/4528—Joints
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/42—Details of probe positioning or probe attachment to the patient
- A61B8/4245—Details of probe positioning or probe attachment to the patient involving determining the position of the probe, e.g. with respect to an external reference frame or to the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/485—Diagnostic techniques involving measuring strain or elastic properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/0026—Stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/003—Destruction of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Optics & Photonics (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Theoretical Computer Science (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Electromagnetism (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Plasma & Fusion (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Mechanical Engineering (AREA)
- Surgical Instruments (AREA)
Description
本願は、以下の出願の優先権を主張し、参照により組み込む。
2010年3月16日に出願された米国特許出願第12/725450号
2010年1月11日に出願された米国特許出願第12/685655号
2009年10月12日に出願された米国仮特許出願第61/250857号
2009年10月31日に出願された米国仮特許出願第61/256983号
2009年11月16日に出願された米国仮特許出願第61/261741号
2009年12月30日に出願された米国仮特許出願第61/291359号
2010年2月10日に出願された米国仮特許出願第61/303307号
2010年5月21日に出願された米国仮特許出願第61/347375号
2010年8月27日に出願された米国仮特許出願第61/377908号
米国特許出願第11/583569号、第12/762938号、第11/583656号、第12/247969号、第10/633726号、第09/721526号、第10/780405号、第09/747310号、第12/202195号、第11/619996号、第09/696076号、第11/016701号、第12/887,178号、第12/390975号、第12/887178号、第12/887211号、第12/887232号
Claims (20)
- 患者にエネルギーを送達する装置であって、
1またはそれ以上の腎神経が周囲に位置する患者の腎血管に隣接する対象領域に、超音波エネルギーを送達するように構成されるエネルギー源と、
プロセッサとを含み、前記プロセッサは、
前記腎血管の位置に関連するインプットを受信し、
動脈位置と神経位置とを関連付けるモデルに基づいて、前記1またはそれ以上の腎神経のうちの少なくとも一つを含む対象領域の位置に関するアウトプットを決定し、かつ
前記エネルギー源の制御システムに前記アウトプットを提供するように構成され、前記アウトプットの提供により、前記制御システムは、前記エネルギー源に、患者の外側から前記対象領域に超音波エネルギーを送達させることが可能となっている、装置。 - 前記エネルギー源は焦点式超音波エネルギーを提供するように構成される、請求項1に記載の装置。
- 前記エネルギー源は非焦点式超音波エネルギーを提供するように構成される、請求項1に記載の装置。
- 前記エネルギー源は、前記超音波エネルギーを提供して前記1またはそれ以上の腎神経のうちの少なくとも一つの部分的なアブレーションを達成するように構成される、請求項1に記載の装置。
- 前記エネルギー源は、前記超音波エネルギーを送達して前記1またはそれ以上の腎神経のうちの少なくとも一つの完全なアブレーションを達成するように構成される、請求項1に記載の装置。
- 前記エネルギー源は、患者の皮膚を介して前記超音波エネルギーを送達するように構成される、請求項1に記載の装置。
- 前記エネルギー源は、前記超音波エネルギーを送達して、前記超音波エネルギーの経路の範囲内にある組織を損傷せずに、前記1またはそれ以上の腎神経のうちの少なくとも一つを調節するように構成される、請求項1に記載の装置。
- 画像信号を提供するための撮像デバイスをさらに含み、前記プロセッサは前記インプットとして前記画像信号を受信するように構成される、請求項1に記載の装置。
- 前記撮像デバイスは、CTデバイス、MRIデバイス、サーモグラフィデバイス、赤外線撮像デバイス、光コヒーレンス・トモグラフィーデバイス、光音響撮像デバイス、PET撮像デバイス、SPECT撮像デバイス、又は超音波デバイスを含む、請求項8に記載の装置。
- 前記プロセッサは、前記腎血管の位置を特定するように構成される、請求項1に記載の装置。
- 前記プロセッサは、ドップラー三角測量手法を使用して前記腎血管の位置を特定するように構成される、請求項10に記載の装置。
- 前記エネルギー源はさらに、前記患者に試験エネルギーを送達するように構成されており、前記試験エネルギーは、当該試験エネルギーによって生じる反応を確認するためのものである、請求項1に記載の装置。
- 前記腎血管の撮像用にBモード超音波を提供するための撮像デバイスをさらに含む、請求項1に記載の装置。
- 前記腎血管の内側に配置される基準体と、
前記腎血管の内側の前記基準体を検出する検出デバイスとをさらに含み、
前記プロセッサが、検出された前記基準体の三次元座標を決定するように構成される、請求項1に記載の装置。 - 前記基準体は血管内カテーテルに接続される、請求項14に記載の装置。
- 前記基準体は、外部信号に応答するように構成される受動的基準体である、請求項14に記載の装置。
- 前記基準体は、その位置を前記検出デバイスに伝送する能動的基準体である、請求項14に記載の装置。
- 前記基準体は、超音波の短パルスを伝送して、患者の内側にあるその位置を信号で伝えるように構成される、請求項14に記載の装置。
- 前記対象領域における前記超音波エネルギーの範囲は100W/cm2〜2500W/cm2の間である、請求項1に記載の装置。
- 前記プロセッサは、前記対象領域に40度〜60度の間の温度場を創出するための超音波強度を決定するように構成される、請求項1に記載の装置。
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25085709P | 2009-10-12 | 2009-10-12 | |
US61/250,857 | 2009-10-12 | ||
US25698309P | 2009-10-31 | 2009-10-31 | |
US61/256,983 | 2009-10-31 | ||
US26174109P | 2009-11-16 | 2009-11-16 | |
US61/261,741 | 2009-11-16 | ||
US29135909P | 2009-12-30 | 2009-12-30 | |
US61/291,359 | 2009-12-30 | ||
US12/685,655 | 2010-01-11 | ||
US12/685,655 US8295912B2 (en) | 2009-10-12 | 2010-01-11 | Method and system to inhibit a function of a nerve traveling with an artery |
US30330710P | 2010-02-10 | 2010-02-10 | |
US61/303,307 | 2010-02-10 | ||
US12/725,450 | 2010-03-16 | ||
US12/725,450 US20110118600A1 (en) | 2009-11-16 | 2010-03-16 | External Autonomic Modulation |
US34737510P | 2010-05-21 | 2010-05-21 | |
US61/347,375 | 2010-05-21 | ||
US37790810P | 2010-08-27 | 2010-08-27 | |
US61/377,908 | 2010-08-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012533385A Division JP5794580B2 (ja) | 2009-10-12 | 2010-10-11 | エネルギーによる神経調節 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015165894A JP2015165894A (ja) | 2015-09-24 |
JP5943441B2 true JP5943441B2 (ja) | 2016-07-05 |
Family
ID=46208933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012533385A Active JP5794580B2 (ja) | 2009-10-12 | 2010-10-11 | エネルギーによる神経調節 |
JP2015082029A Active JP5943441B2 (ja) | 2009-10-12 | 2015-04-13 | エネルギーによる神経調節 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012533385A Active JP5794580B2 (ja) | 2009-10-12 | 2010-10-11 | エネルギーによる神経調節 |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP2488250B1 (ja) |
JP (2) | JP5794580B2 (ja) |
KR (2) | KR101545775B1 (ja) |
CN (2) | CN102164542B (ja) |
AU (1) | AU2010307029B2 (ja) |
BR (1) | BR112012008538A2 (ja) |
CA (1) | CA2777228A1 (ja) |
HK (1) | HK1156491A1 (ja) |
IL (2) | IL219083A (ja) |
MY (1) | MY160595A (ja) |
RU (1) | RU2523129C2 (ja) |
WO (2) | WO2011046879A1 (ja) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
US20080039746A1 (en) | 2006-05-25 | 2008-02-14 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
EP2376011B1 (en) | 2009-01-09 | 2019-07-03 | ReCor Medical, Inc. | Apparatus for treatment of mitral valve insufficiency |
US8295912B2 (en) | 2009-10-12 | 2012-10-23 | Kona Medical, Inc. | Method and system to inhibit a function of a nerve traveling with an artery |
EP2493569B1 (en) | 2009-10-30 | 2015-09-30 | ReCor Medical, Inc. | Apparatus for treatment of hypertension through percutaneous ultrasound renal denervation |
KR20120087962A (ko) * | 2009-10-30 | 2012-08-07 | 사운드 인터벤션스, 인코포레이티드 | 초음파 신장 신경차단술을 통한 고혈압의 비-침습적 치료를 위한 방법 및 장치 |
US20110112400A1 (en) * | 2009-11-06 | 2011-05-12 | Ardian, Inc. | High intensity focused ultrasound catheter apparatuses, systems, and methods for renal neuromodulation |
CN102883659A (zh) * | 2010-01-19 | 2013-01-16 | 美敦力阿迪安卢森堡有限公司 | 通过立体定向放疗用于肾神经调节的方法和设备 |
EP2706939A4 (en) * | 2011-05-09 | 2015-05-27 | Cyberheart Inc | DEVICE, SYSTEM AND METHOD FOR RENOVASCULAR TREATMENT FOR RADIOSURGICAL RELIEF HYPERTENSION |
JP2014525781A (ja) * | 2011-07-12 | 2014-10-02 | ベルブ メディカル, インコーポレイテッド | 腎盂を通した腎神経の脱神経 |
EP2750765A4 (en) * | 2011-09-01 | 2015-07-01 | Perseus Biomed Inc | METHOD AND SYSTEM FOR MODULATING TISSUE |
JP2013122443A (ja) * | 2011-11-11 | 2013-06-20 | Hideo Ando | 生体活動測定方法、生体活動測定装置、生体活動検出信号の転送方法および生体活動情報を利用したサービスの提供方法 |
AU2012347470B2 (en) | 2011-12-09 | 2017-02-02 | Medtronic Ireland Manufacturing Unlimited Company | Therapeutic neuromodulation of the hepatic system |
US9119550B2 (en) * | 2012-03-30 | 2015-09-01 | Siemens Medical Solutions Usa, Inc. | Magnetic resonance and ultrasound parametric image fusion |
WO2013149684A1 (en) * | 2012-04-02 | 2013-10-10 | Flux Medical N.V. | Implant device and system for ablation of a renal arterial wall from the inside |
US20150173619A1 (en) * | 2012-04-17 | 2015-06-25 | Collage Medical Imaging Ltd. | Organ mapping system using an optical coherence tomography probe |
CN104519817B (zh) | 2012-04-24 | 2017-11-10 | 西比姆公司 | 用于颈动脉体摘除的血管内导管和方法 |
CN104394933A (zh) * | 2012-04-27 | 2015-03-04 | 美敦力阿迪安卢森堡有限公司 | 肾神经调制的超声装置、系统、和方法 |
US9439722B2 (en) | 2012-05-09 | 2016-09-13 | Biosense Webster (Israel) Ltd. | Ablation targeting nerves in or near the inferior vena cava and/or abdominal aorta for treatment of hypertension |
WO2013181660A1 (en) | 2012-06-01 | 2013-12-05 | Cibiem, Inc. | Methods and devices for cryogenic carotid body ablation |
WO2013181667A1 (en) | 2012-06-01 | 2013-12-05 | Cibiem, Inc. | Percutaneous methods and devices for carotid body ablation |
CN107440720B (zh) * | 2012-06-27 | 2020-09-08 | 东芝医疗系统株式会社 | 超声波诊断装置以及图像数据的校正方法 |
US9955946B2 (en) | 2014-03-12 | 2018-05-01 | Cibiem, Inc. | Carotid body ablation with a transvenous ultrasound imaging and ablation catheter |
EP2866669A4 (en) | 2012-06-30 | 2016-04-20 | Cibiem Inc | ABLATION OF CAROTID BODY VIA DIRECTED ENERGY |
EP2869751A4 (en) * | 2012-07-04 | 2016-04-13 | Cibiem Inc | DEVICES AND SYSTEMS FOR HEADACHE BODY ABATEMENT |
US11167154B2 (en) | 2012-08-22 | 2021-11-09 | Medtronic, Inc. | Ultrasound diagnostic and therapy management system and associated method |
WO2014047411A1 (en) * | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
AU2014208382A1 (en) | 2013-01-24 | 2015-07-23 | Tylerton International Holdings Inc. | Body structure imaging |
CN104994783B (zh) * | 2013-02-08 | 2018-11-13 | 柯惠有限合伙公司 | 用于肺神经切除术的系统和方法 |
AU2014229201A1 (en) * | 2013-03-11 | 2015-09-10 | Tylerton International Inc. | Modeling the autonomous nervous system and uses thereof |
CN105074050B (zh) | 2013-03-14 | 2019-02-15 | 瑞蔻医药有限公司 | 电镀或涂覆超声换能器的方法 |
US10456605B2 (en) | 2013-03-14 | 2019-10-29 | Recor Medical, Inc. | Ultrasound-based neuromodulation system |
JP2014239871A (ja) * | 2013-05-07 | 2014-12-25 | 安東 秀夫 | 生体活動検出方法、生体活動測定装置、生体活動検出信号の転送方法および生体活動情報を利用したサービスの提供方法 |
EP3003191A4 (en) | 2013-06-05 | 2017-02-08 | Metavention, Inc. | Modulation of targeted nerve fibers |
WO2015033319A2 (en) | 2013-09-08 | 2015-03-12 | Shlomo Ben-Haim | Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease |
CN105939758A (zh) * | 2013-11-04 | 2016-09-14 | 引导干预有限公司 | 用于以离焦超声执行热支气管成形术的方法和设备 |
US20160317129A1 (en) * | 2013-12-18 | 2016-11-03 | Koninklijke Philips N.V. | System and method for ultrasound and computed tomography image registration for sonothrombolysis treatment |
WO2015104672A2 (en) | 2014-01-10 | 2015-07-16 | Tylerton International Holdings Inc. | Detection of scar and fibrous cardiac zones |
KR101654675B1 (ko) * | 2014-02-03 | 2016-09-06 | 삼성메디슨 주식회사 | 광음향 물질을 이용하여 진단 영상을 생성하는 방법, 장치 및 시스템. |
US11298028B2 (en) | 2014-02-12 | 2022-04-12 | Koninklijke Philips N.V. | Temperature distribution determination apparatus |
JP6560244B2 (ja) * | 2014-02-26 | 2019-08-14 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 管腔内ヒストトリプシーを実行するためのシステム及びその動作方法 |
EP3206748B1 (en) | 2014-10-17 | 2024-04-17 | Koninklijke Philips N.V. | An ultrasound patch for ultrasound hyperthermia and ablation therapy |
EP3220830B1 (en) | 2014-11-18 | 2019-05-15 | Koninklijke Philips N.V. | Apparatus for visualizing tissue property |
CN107427191B (zh) * | 2015-03-30 | 2019-09-13 | 泰尔茂株式会社 | 图像处理装置和方法、程序 |
DE102015106560B4 (de) * | 2015-04-28 | 2018-10-25 | Audisense Gmbh | Hörprothese |
EP3325086B1 (en) | 2015-07-21 | 2024-09-11 | Koninklijke Philips N.V. | System for stimulating renal nerves |
EA032247B1 (ru) * | 2015-07-22 | 2019-04-30 | Сергей Владимирович ПЛЕТНЕВ | Устройство и система для локальной магнитотерапии |
US20190038909A1 (en) * | 2016-02-10 | 2019-02-07 | Helium 3 Resources Pty Ltd | A Therapeutic Method and Device Therefor |
KR101672535B1 (ko) * | 2016-03-07 | 2016-11-04 | 알피니언메디칼시스템 주식회사 | 3차원 정보를 이용한 hifu 장치와 시스템 및 hifu 장치 제어방법 |
US20190192033A1 (en) * | 2016-05-05 | 2019-06-27 | BestBrian Ltd. | Neurofeedback systems and methods |
US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
AU2017348440C1 (en) * | 2016-10-31 | 2023-07-20 | General Electric Company | Techniques for neuromodulation |
AU2017254920B2 (en) * | 2016-11-10 | 2019-04-04 | Gimer Medical Co. Ltd. | Method of reducing renal hypertension and computer-readable medium |
US20200094080A1 (en) * | 2017-03-20 | 2020-03-26 | Sonivie Ltd. | Method for treating heart failure by improving ejection fraction of a patient |
CN107169981B (zh) * | 2017-05-12 | 2020-07-07 | 西南交通大学 | 一种道砟颗粒三维廓形的检测方法及装置 |
CN110997066B (zh) * | 2017-06-21 | 2022-08-05 | 香港理工大学 | 用于超声脊髓刺激的设备和方法 |
KR101861963B1 (ko) * | 2017-06-30 | 2018-05-28 | 한국과학기술원 | 자극 방법 및 이를 수행하는 장치들 |
US11511136B2 (en) | 2017-11-17 | 2022-11-29 | The Research Foundation For The State University Of New York | Method for treating damaged peripheral nerves using x-ray microbeam irradiation |
CN108846821B (zh) * | 2018-04-27 | 2022-01-11 | 电子科技大学 | 一种基于小波变换的细胞神经网络热区域融合方法 |
US11235178B2 (en) * | 2018-09-04 | 2022-02-01 | General Electric Company | Neuromodulation energy application techniques |
WO2020227877A1 (en) * | 2019-05-13 | 2020-11-19 | Covidien Lp | System and method for selectively sealing small vessels |
US11230217B2 (en) | 2019-07-02 | 2022-01-25 | Command Alkon Incorporated | Device and method for determining cleanliness of a rotating drum of a fresh concrete mixer truck |
CN110292359B (zh) * | 2019-07-09 | 2021-01-08 | 浙江大学 | 一种无标记全光学神经调控与成像的方法与装置 |
EP4355421A1 (en) * | 2021-06-15 | 2024-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems, and methods for pain suppression through targeted peripheral nerve application of focused ultrasound |
WO2024187150A1 (en) * | 2023-03-09 | 2024-09-12 | Eyesonix Inc. | Method and treatment of the eye with ultrasound |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3274437A (en) * | 1963-11-20 | 1966-09-20 | Thompson Ramo Wooldridge Inc | High intensity radiant energy source |
DE3932967A1 (de) * | 1989-10-03 | 1991-04-11 | Wolf Gmbh Richard | Ultraschall-stosswellenwandler |
JP3300419B2 (ja) * | 1991-08-21 | 2002-07-08 | 株式会社東芝 | 血栓溶解治療装置 |
EP0627206B1 (en) * | 1993-03-12 | 2002-11-20 | Kabushiki Kaisha Toshiba | Apparatus for ultrasound medical treatment |
JPH0747079A (ja) * | 1993-08-05 | 1995-02-21 | Toshiba Corp | 超音波治療装置 |
US20050182297A1 (en) * | 1996-10-04 | 2005-08-18 | Dietrich Gravenstein | Imaging scope |
JP4322322B2 (ja) * | 1997-03-31 | 2009-08-26 | 株式会社東芝 | 超音波治療装置 |
US6259945B1 (en) * | 1999-04-30 | 2001-07-10 | Uromed Corporation | Method and device for locating a nerve |
US7510536B2 (en) | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
US7706882B2 (en) * | 2000-01-19 | 2010-04-27 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area |
US6506171B1 (en) * | 2000-07-27 | 2003-01-14 | Insightec-Txsonics, Ltd | System and methods for controlling distribution of acoustic energy around a focal point using a focused ultrasound system |
US6845267B2 (en) * | 2000-09-28 | 2005-01-18 | Advanced Bionics Corporation | Systems and methods for modulation of circulatory perfusion by electrical and/or drug stimulation |
US6679855B2 (en) * | 2000-11-07 | 2004-01-20 | Gerald Horn | Method and apparatus for the correction of presbyopia using high intensity focused ultrasound |
US20070135875A1 (en) * | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7653438B2 (en) * | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US7162303B2 (en) * | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7074218B2 (en) * | 2003-06-30 | 2006-07-11 | Ethicon, Inc. | Multi-modality ablation device |
US7854733B2 (en) * | 2004-03-24 | 2010-12-21 | Biosense Webster, Inc. | Phased-array for tissue treatment |
US8727987B2 (en) * | 2004-05-06 | 2014-05-20 | Nanyang Technological University | Mechanical manipulator for HIFU transducers |
CA2587522A1 (en) * | 2004-11-15 | 2006-05-26 | Christopher Decharms | Stimulation of neural tissue with light |
US7553284B2 (en) * | 2005-02-02 | 2009-06-30 | Vaitekunas Jeffrey J | Focused ultrasound for pain reduction |
EP1909908B1 (en) * | 2005-06-02 | 2011-03-30 | Cancercure Technology AS | Ultrasound treatment system |
JP4686269B2 (ja) * | 2005-06-22 | 2011-05-25 | 株式会社日立メディコ | 超音波治療装置 |
EP1921976A2 (en) * | 2005-08-12 | 2008-05-21 | University of Washington | Method and apparatus for preparing organs and tissues for laparoscopic surgery |
US20070038115A1 (en) * | 2005-08-12 | 2007-02-15 | Quigley David P | High intensity ultrasound apparatus methods and systems |
US7621873B2 (en) * | 2005-08-17 | 2009-11-24 | University Of Washington | Method and system to synchronize acoustic therapy with ultrasound imaging |
EP1933941A2 (en) * | 2005-08-25 | 2008-06-25 | Philip R. Houle | Treatment systems for delivery of sensitizer solutions |
US20070167798A1 (en) * | 2005-11-23 | 2007-07-19 | Cai Anming H | Contrast agent augmented ultrasound therapy system with ultrasound imaging guidance for thrombus treatment |
US20080039746A1 (en) * | 2006-05-25 | 2008-02-14 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US7469572B2 (en) * | 2006-07-17 | 2008-12-30 | Kci Licensing, Inc. | Measurement of moisture vapor transfer rate |
US7871406B2 (en) * | 2006-08-04 | 2011-01-18 | INTIO, Inc. | Methods for planning and performing thermal ablation |
DE102007007099B4 (de) * | 2007-02-13 | 2015-04-30 | Siemens Aktiengesellschaft | Medizinische Einrichtung mit wenigstens einem zur Erzeugung von hochintensivem fokussiertem Ultraschall ausgebildeten Wandler und mit einem Magnetresonanzgerät sowie zugehöriger Ultraschallwandler und Verfahren zur Erstellung von Magnetresonanzaufnahmen |
WO2008144274A2 (en) * | 2007-05-14 | 2008-11-27 | Sono Esthetx, Inc. | Method, system, and apparatus for line-focused ultrasound therapy |
EP2190532A1 (en) * | 2007-07-31 | 2010-06-02 | M. Bret Schneider | Device and method for hypertension treatment by non-invasive stimulation to vascular baroreceptors |
US8052604B2 (en) * | 2007-07-31 | 2011-11-08 | Mirabilis Medica Inc. | Methods and apparatus for engagement and coupling of an intracavitory imaging and high intensity focused ultrasound probe |
US20090149782A1 (en) * | 2007-12-11 | 2009-06-11 | Donald Cohen | Non-Invasive Neural Stimulation |
EP2248122A1 (en) * | 2008-02-25 | 2010-11-10 | Inventive Medical Limited | Medical training method and apparatus |
US20090221908A1 (en) * | 2008-03-01 | 2009-09-03 | Neil David Glossop | System and Method for Alignment of Instrumentation in Image-Guided Intervention |
JP4283330B2 (ja) * | 2008-06-24 | 2009-06-24 | 株式会社東芝 | 超音波治療装置 |
-
2010
- 2010-10-11 WO PCT/US2010/052193 patent/WO2011046879A1/en active Application Filing
- 2010-10-11 JP JP2012533385A patent/JP5794580B2/ja active Active
- 2010-10-11 RU RU2012119540/14A patent/RU2523129C2/ru active IP Right Revival
- 2010-10-11 EP EP10823909.6A patent/EP2488250B1/en active Active
- 2010-10-11 KR KR1020127012159A patent/KR101545775B1/ko active IP Right Grant
- 2010-10-11 BR BR112012008538A patent/BR112012008538A2/pt not_active IP Right Cessation
- 2010-10-11 MY MYPI2012001623A patent/MY160595A/en unknown
- 2010-10-11 CN CN201080002316.4A patent/CN102164542B/zh active Active
- 2010-10-11 CN CN201080052675.0A patent/CN102740925B/zh active Active
- 2010-10-11 CA CA2777228A patent/CA2777228A1/en not_active Abandoned
- 2010-10-11 EP EP10810835.8A patent/EP2344039B1/en active Active
- 2010-10-11 KR KR1020157004249A patent/KR101567285B1/ko active IP Right Grant
- 2010-10-11 AU AU2010307029A patent/AU2010307029B2/en active Active
- 2010-10-11 WO PCT/US2010/052197 patent/WO2011046880A2/en active Application Filing
-
2011
- 2011-10-13 HK HK11110882.7A patent/HK1156491A1/zh unknown
-
2012
- 2012-04-05 IL IL219083A patent/IL219083A/en not_active IP Right Cessation
-
2015
- 2015-04-13 JP JP2015082029A patent/JP5943441B2/ja active Active
- 2015-05-06 IL IL238653A patent/IL238653A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR101567285B1 (ko) | 2015-11-09 |
IL219083A0 (en) | 2012-06-28 |
EP2344039B1 (en) | 2015-11-25 |
IL238653A0 (en) | 2015-06-30 |
RU2012119540A (ru) | 2013-11-20 |
KR20120127708A (ko) | 2012-11-23 |
EP2488250A4 (en) | 2012-11-21 |
AU2010307029A1 (en) | 2012-05-03 |
BR112012008538A2 (pt) | 2016-04-05 |
IL219083A (en) | 2015-06-30 |
JP2015165894A (ja) | 2015-09-24 |
KR101545775B1 (ko) | 2015-08-19 |
CN102740925A (zh) | 2012-10-17 |
RU2523129C2 (ru) | 2014-07-20 |
EP2344039A4 (en) | 2012-01-04 |
JP2013507198A (ja) | 2013-03-04 |
WO2011046879A1 (en) | 2011-04-21 |
WO2011046880A3 (en) | 2011-08-25 |
EP2488250A2 (en) | 2012-08-22 |
JP5794580B2 (ja) | 2015-10-14 |
CA2777228A1 (en) | 2011-04-21 |
HK1156491A1 (zh) | 2012-06-15 |
CN102740925B (zh) | 2015-02-18 |
AU2010307029B2 (en) | 2014-07-31 |
CN102164542B (zh) | 2015-09-30 |
EP2488250B1 (en) | 2015-11-25 |
KR20150029036A (ko) | 2015-03-17 |
WO2011046880A2 (en) | 2011-04-21 |
EP2344039A1 (en) | 2011-07-20 |
CN102164542A (zh) | 2011-08-24 |
MY160595A (en) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5943441B2 (ja) | エネルギーによる神経調節 | |
US8556834B2 (en) | Flow directed heating of nervous structures | |
US9352171B2 (en) | Nerve treatment system | |
US8992447B2 (en) | Energetic modulation of nerves | |
US8986211B2 (en) | Energetic modulation of nerves | |
EP3005944A1 (en) | Energetic modulation of nerves | |
US11998266B2 (en) | Intravascular energy delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150804 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160322 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160419 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160519 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5943441 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |